Activation of polycystin-1 signaling by binding of stalk-derived peptide agonists
Shristi Pawnikar,
Brenda S Magenheimer,
Keya Joshi,
Ericka Nevarez-Munoz,
Allan Haldane,
Robin L Maser,
Yinglong Miao
Affiliations
Shristi Pawnikar
Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, United States
Brenda S Magenheimer
Clinical Laboratory Sciences, University of Kansas Medical Center, Kansas City, United States; The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, United States
Department of Physics, and Center for Biophysics and Computational Biology, Temple University, Philadelphia, United States
Robin L Maser
Clinical Laboratory Sciences, University of Kansas Medical Center, Kansas City, United States; The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, United States; Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, United States
Polycystin-1 (PC1) is the protein product of the PKD1 gene whose mutation causes autosomal dominant Polycystic Kidney Disease (ADPKD). PC1 is an atypical G protein-coupled receptor (GPCR) with an autocatalytic GAIN domain that cleaves PC1 into extracellular N-terminal and membrane-embedded C-terminal (CTF) fragments. Recently, activation of PC1 CTF signaling was shown to be regulated by a stalk tethered agonist (TA), resembling the mechanism observed for adhesion GPCRs. Here, synthetic peptides of the first 9- (p9), 17- (p17), and 21-residues (p21) of the PC1 stalk TA were shown to re-activate signaling by a stalkless CTF mutant in human cell culture assays. Novel Peptide Gaussian accelerated molecular dynamics (Pep-GaMD) simulations elucidated binding conformations of p9, p17, and p21 and revealed multiple specific binding regions to the stalkless CTF. Peptide agonists binding to the TOP domain of PC1 induced close TOP-putative pore loop interactions, a characteristic feature of stalk TA-mediated PC1 CTF activation. Additional sequence coevolution analyses showed the peptide binding regions were consistent with covarying residue pairs identified between the TOP domain and the stalk TA. These insights into the structural dynamic mechanism of PC1 activation by TA peptide agonists provide an in-depth understanding that will facilitate the development of therapeutics targeting PC1 for ADPKD treatment.
